{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-256110","form_type":"8-K","ticker":"AURA","cik":"0001501796","company_name":"Aura Biosciences, Inc.","filed_at":"2022-10-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.887331+00:00","generated_at":"2026-06-23T05:56:38.187319+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Aura reports Phase 2 interim data: 89% tumor control, significant growth rate reduction for choroidal melanoma","bullets":["Interim Phase 2 data for belzupacap sarotalocan (AU-011) in early-stage choroidal melanoma show 88.9% (8/9) tumor control rate at therapeutic regimen.","Statistically significant reduction in tumor growth rate of -0.296 mm/year (p=0.0007) vs. documented historical growth.","Visual acuity preservation rate of 88.9% (8/9) in highest dose cohorts; most tumors were near fovea or optic disc.","No dose-limiting toxicities or treatment-related serious adverse events reported; mild anterior inflammation in 20%.","Data support planned pivotal program; company held virtual investor day on October 3, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-256110","json":"https://secwatch.observer/filing/0001193125-22-256110.json","markdown":"https://secwatch.observer/filing/0001193125-22-256110.md","text":"https://secwatch.observer/filing/0001193125-22-256110.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501796/000119312522256110/0001193125-22-256110-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501796/000119312522256110/d251752d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T05:56:38.187319+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}